Radiation Induced Lymphocyte Apoptosis: An Effective Way of “Tailoring” Radiotherapy to the Right Patients Only?

Cozzarini, C.

doi:10.1016/j.ebiom.2015.11.014

Cited by 6 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We are now entering a new era of personalized treatment [39] and radiation oncology is surely a good example with the development of a toxicity biomarker whatever the fractionation used, particularly in prostate and breast cancers.…”

Section: Discussionmentioning

confidence: 99%

Radiation-Induced Lymphocyte Apoptosis and Chromosomic Aberrations for Prediction of Toxicities in Patients Treated by Hypofractionated Radiotherapy for Breast or Prostate Cancers

Azria¹,

Haviland²,

Brengues³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: In trials using normofractionated regimen, the radiation-induced lymphocyte apoptosis (RILA) and the chromosomal damage assays (CDA) have shown prognostic roles of radiation-induced adverse events. The main objectives here were to validate RILA and CDA in extreme and moderate hypofractionation regimens for breast (FAST) and prostate (CHHiP) cancers. Methods: Blood samples were collected from 400 volunteers included in FAST and CHHiP trials. The primary endpoints (PE) were first change in photographic breast appearance and first grade ≥2 RTOG bladder or bowel toxicity (BBT) in FAST and CHHiP, respectively. The secondary endpoints was first grade ≥2 breast clinical changes (BCC) in FAST and BBT using different scales in CHHiP. Results: 103 FAST and 297 CHHiP patients with lab and clinical data were included. In FAST trial, no significant association of RILA with the primary endpoint was observed. A significant association of higher RILA levels with lower risk of any RIAE was found. The risk of developing grade ≥2 RIAE decreased significantly for patients with RILA≥24% compared to those with RILA≤16% with a HR of 0.50 (95%CI 0.25-1.00, p=0.012). Concerning chromosomic aberrations, no significant associations were found with change in photographic breast appearance nor with the secondary endpoint of any RIAE. In CHHiP trial, a decreased risk of grade≥2 RTOG bladder or bowel RIAE was observed for increasing values of RILA (HR 0.97, 95%CI 0.94-1.01, p=0.11) but did not reach statistical significance. Concerning chromosomic aberrations, we found significant association of higher levels of micronuclei per cell with lower risk of gr2+ RTOGAE (p=0.021 for trend test across tertiles; p=0.023 for upper vs lower tertile). Conclusions: This study is the first to evaluate RILA and CDA as predictors of late effects after breast and prostate RT in the “hypofractionation” era. Development of toxicity biomarkers whatever the RT fractionation are urgently needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiation-Induced Lymphocyte Apoptosis and Chromosomic Aberrations for Prediction of Toxicities in Patients Treated by Hypofractionated Radiotherapy for Breast or Prostate Cancers

Azria¹,

Haviland²,

Brengues³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…However, since no strong correlation has been found between low RILA and an increased risk of radiation-induced toxicities, radiotherapy should be maintained when it is the standard of care. Although the mechanism of this inverse association is not completely clear, it may possibly be related to the delay of cells in recognizing the radiation-induced cell damage and initiating apoptosis, with a consequently increased risk of toxicity and, theoretically, of cancer radioresistance and reduced tumor control for low-RILA patients [52]. However, to date, no correlation between low RILA values and low tumor control has been described in the literature.…”

Section: Clinical Datamentioning

confidence: 99%

Improving Patients’ Life Quality after Radiotherapy Treatment by Predicting Late Toxicities

Lapierre

Bourillon

Larroque

et al. 2022

Cancers

View full text Add to dashboard Cite

Personalized treatment and precision medicine have become the new standard of care in oncology and radiotherapy. Because treatment outcomes have considerably improved over the last few years, permanent side-effects are becoming an increasingly significant issue for cancer survivors. Five to ten percent of patients will develop severe late toxicity after radiotherapy. Identifying these patients before treatment start would allow for treatment adaptation to minimize definitive side effects that could impair their long-term quality of life. Over the last decades, several tests and biomarkers have been developed to identify these patients. However, out of these, only the Radiation-Induced Lymphocyte Apoptosis (RILA) assay has been prospectively validated in multi-center cohorts. This test, based on a simple blood draught, has been shown to be correlated with late radiation-induced toxicity in breast, prostate, cervical and head and neck cancer. It could therefore greatly improve decision making in precision radiation oncology. This literature review summarizes the development and bases of this assay, as well as its clinical results and compares its results to the other available assays.

show abstract

Radiotherapy toxicity

Panchal,

Mule,

Wankhede

et al. 2024

Public Health and Toxicology Issues Drug Research, Volume 2

View full text Add to dashboard Cite

Radiation Induced Lymphocyte Apoptosis: An Effective Way of “Tailoring” Radiotherapy to the Right Patients Only?

Cited by 6 publications

References 10 publications

Radiation-Induced Lymphocyte Apoptosis and Chromosomic Aberrations for Prediction of Toxicities in Patients Treated by Hypofractionated Radiotherapy for Breast or Prostate Cancers

Radiation-Induced Lymphocyte Apoptosis and Chromosomic Aberrations for Prediction of Toxicities in Patients Treated by Hypofractionated Radiotherapy for Breast or Prostate Cancers

Improving Patients’ Life Quality after Radiotherapy Treatment by Predicting Late Toxicities

Radiotherapy toxicity

Contact Info

Product

Resources

About